{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:09:35Z","timestamp":1790111375793,"version":"4.0.1"},"reference-count":132,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ejpb.2026.115179","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T23:50:48Z","timestamp":1783468248000},"page":"115179","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Ageing-driven gastrointestinal variability in Parkinson\u2019s disease: implications for oral levodopa pharmacokinetics and formulation design"],"prefix":"10.1016","volume":"226","author":[{"given":"Muzaffaruddin Ahmed","family":"Madny","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khushwant S.","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejpb.2026.115179_b0005","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s12883-025-04191-8","article-title":"Global, regional and national burden of Parkinson\u2019s disease in people over 55 years of age: A systematic analysis of the global burden of disease study, 1991\u20132021","volume":"25","author":"Peng","year":"2025","journal-title":"BMC Neurol."},{"key":"10.1016\/j.ejpb.2026.115179_b0010","doi-asserted-by":"crossref","unstructured":"Su, D., Cui, Y., He, C., Yin, P., Bai, R., Zhu, J., Lam, J.S., Zhang, J., Yan, R., Zheng, X. and Wu, J., 2025. Projections for prevalence of Parkinson\u2019s disease and its driving factors in 195 countries and territories to 2050: modelling study of Global Burden of Disease Study 2021.bmj,388.","DOI":"10.1136\/bmj-2024-080952"},{"key":"10.1016\/j.ejpb.2026.115179_b0015","unstructured":"Sharma, A., Voigt, R.M., Goetz, C.G. and Keshavarzian, A., 2022. PARKINSON\u2019S DISEASE AND THE GUT: A PRIMER FOR GASTROENTEROLOGISTS.Official journal of the American College of Gastroenterology| ACG, pp.10-14309."},{"issue":"1","key":"10.1016\/j.ejpb.2026.115179_b0020","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41531-022-00295-x","article-title":"Gastrointestinal involvement in Parkinson\u2019s disease: pathophysiology, diagnosis, and management","volume":"8","author":"Warnecke","year":"2022","journal-title":"npj Parkinson's Dis."},{"issue":"6","key":"10.1016\/j.ejpb.2026.115179_b0025","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00415-025-13138-5","article-title":"The gut\u2013brain axis in early Parkinson\u2019s disease: from prodrome to prevention","volume":"272","author":"Oliver","year":"2025","journal-title":"J. Neurol."},{"key":"10.1016\/j.ejpb.2026.115179_b0030","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1415463","article-title":"The interplay between gut microbiota and the brain-gut axis in Parkinson\u2019s disease treatment","volume":"15","author":"Jia","year":"2024","journal-title":"Front. Neurol."},{"key":"10.1016\/j.ejpb.2026.115179_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2023.106452","article-title":"The impact of advanced age on gastrointestinal characteristics that are relevant to oral drug absorption: An AGePOP review","volume":"187","author":"Stillhart","year":"2023","journal-title":"Eur. J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.ejpb.2026.115179_b0040","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1365-2125.1989.tb03506.x","article-title":"The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa","volume":"28","author":"Robertson","year":"1989","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.ejpb.2026.115179_b0045","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3390\/gidisord6010022","article-title":"Main disorders of gastrointestinal tract in older people: an overview","volume":"6","author":"Gallo","year":"2024","journal-title":"Gastrointestinal Disorders"},{"issue":"1","key":"10.1016\/j.ejpb.2026.115179_b0050","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s40495-025-00425-y","article-title":"Absorption to excretion: The aging body\u2019s take on drugs\u2013A review of pharmacokinetic changes and their impact on medication management","volume":"11","author":"Ruiz","year":"2025","journal-title":"Current Pharmacology Reports"},{"key":"10.1016\/j.ejpb.2026.115179_b0055","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.3389\/fneur.2019.01087","article-title":"Contributions of gut bacteria and diet to drug pharmacokinetics in the treatment of Parkinson\u2019s disease","volume":"10","author":"van Kessel","year":"2019","journal-title":"Front. Neurol."},{"issue":"12","key":"10.1016\/j.ejpb.2026.115179_b0060","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.18632\/aging.101677","article-title":"Aging-dependent decrease in the numbers of enteric neurons, interstitial cells of Cajal and expression of connexin43 in various regions of gastrointestinal tract","volume":"10","author":"Sun","year":"2018","journal-title":"Aging (Albany NY)"},{"issue":"6","key":"10.1016\/j.ejpb.2026.115179_b0065","doi-asserted-by":"crossref","DOI":"10.1111\/nmo.14352","article-title":"Aging of enteric neuromuscular systems in gastrointestinal tract","volume":"34","author":"Nguyen","year":"2022","journal-title":"Neurogastroenterology & Motility"},{"issue":"1","key":"10.1016\/j.ejpb.2026.115179_b0070","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.ydbio.2013.03.015","article-title":"Cellular changes in the enteric nervous system during ageing","volume":"382","author":"Saffrey","year":"2013","journal-title":"Dev. Biol."},{"key":"10.1016\/j.ejpb.2026.115179_b0075","article-title":"Aging through the lens of the gut microbiome: Challenges and therapeutic opportunities","author":"Kanimozhi","year":"2025","journal-title":"Archives of Gerontology and Geriatrics Plus"},{"key":"10.1016\/j.ejpb.2026.115179_b0080","first-page":"1","article-title":"Assessing the gut microbiota composition in older adults: connections to physical activity and healthy ageing","author":"Ramos","year":"2025","journal-title":"GeroScience"},{"key":"10.1016\/j.ejpb.2026.115179_b0085","article-title":"Trends in intestinal aging: From underlying mechanisms to therapeutic strategies","author":"Wang","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"issue":"10","key":"10.1016\/j.ejpb.2026.115179_b0090","doi-asserted-by":"crossref","DOI":"10.1111\/acel.14315","article-title":"The connection between aging, cellular senescence and gut microbiome alterations: A comprehensive review","volume":"23","author":"Jang","year":"2024","journal-title":"Aging Cell"},{"issue":"6","key":"10.1016\/j.ejpb.2026.115179_b0095","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/JLB.3RI0620-405RR","article-title":"Age-related changes in intestinal immunity and the microbiome","volume":"109","author":"Walrath","year":"2021","journal-title":"Journal of Leucocyte Biology"},{"issue":"9","key":"10.1016\/j.ejpb.2026.115179_b0100","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41575-022-00605-x","article-title":"The gut microbiome as a modulator of healthy ageing","volume":"19","author":"Ghosh","year":"2022","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"5","key":"10.1016\/j.ejpb.2026.115179_b0105","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3390\/geriatrics9050110","article-title":"Impact of gut microbiota on aging and frailty: a narrative review of the literature","volume":"9","author":"Escudero-Bautista","year":"2024","journal-title":"Geriatrics"},{"issue":"1","key":"10.1016\/j.ejpb.2026.115179_b0110","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2024.2359677","article-title":"The human gut microbiome and aging","volume":"16","author":"Bradley","year":"2024","journal-title":"Gut Microbes"},{"issue":"6","key":"10.1016\/j.ejpb.2026.115179_b0115","doi-asserted-by":"crossref","first-page":"906","DOI":"10.3904\/kjim.2024.097","article-title":"Tight junction protein changes in irritable bowel syndrome: the relation of age and disease severity","volume":"39","author":"Kim","year":"2024","journal-title":"Korean J. Intern. Med."},{"issue":"19","key":"10.1016\/j.ejpb.2026.115179_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e37883","article-title":"Gut aging: A wane from the normal to repercussion and gerotherapeutic strategies","volume":"10","author":"Abankwah","year":"2024","journal-title":"Heliyon"},{"issue":"1","key":"10.1016\/j.ejpb.2026.115179_b0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-025-01179-x","article-title":"From dysbiosis to longevity: a narrative review into the gut microbiome\u2019s impact on aging","volume":"32","author":"Tseng","year":"2025","journal-title":"J. Biomed. Sci."},{"issue":"1","key":"10.1016\/j.ejpb.2026.115179_b0130","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13073-025-01493-x","article-title":"Microbiome-based therapeutics towards healthier aging and longevity","volume":"17","author":"Kadyan","year":"2025","journal-title":"Genome Med."},{"issue":"6","key":"10.1016\/j.ejpb.2026.115179_b0135","first-page":"324","article-title":"Gastrointestinal Motility Function and Dysfunction in the Elderly Patient: What Are the Effects of Aging?","volume":"40","author":"Patejdl","year":"2024","journal-title":"Visceral Medicine"},{"issue":"4","key":"10.1016\/j.ejpb.2026.115179_b0140","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/NT.0000000000000616","article-title":"Resiliency of the digestive system during aging and the impact of diet","volume":"58","author":"Sanders","year":"2023","journal-title":"Nutr. Today"},{"key":"10.1016\/j.ejpb.2026.115179_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2023.106453","article-title":"Parameters to consider for successful medication use in older adults-An AGePOP review","volume":"187","author":"Hummler","year":"2023","journal-title":"Eur. J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.ejpb.2026.115179_b0150","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S2468-1253(25)00235-3","article-title":"Age-related changes of the gastrointestinal tract","volume":"11","author":"Pilotto","year":"2026","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"24","key":"10.1016\/j.ejpb.2026.115179_b0155","doi-asserted-by":"crossref","DOI":"10.14814\/phy2.14659","article-title":"The influence of interstitial cells of Cajal loss and aging on slow wave conduction velocity in the human stomach","volume":"8","author":"Wang","year":"2021","journal-title":"Physiol. Rep."},{"issue":"4","key":"10.1016\/j.ejpb.2026.115179_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcmgh.2024.101376","article-title":"Inhibition of EZH2 reduces aging-related decline in interstitial cells of Cajal of the mouse stomach","volume":"18","author":"Taheri","year":"2024","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"issue":"9","key":"10.1016\/j.ejpb.2026.115179_b0165","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.3390\/biom13091358","article-title":"The crucial role of the interstitial cells of Cajal in neurointestinal diseases","volume":"13","author":"Choi","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.ejpb.2026.115179_b0170","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2022.979826","article-title":"Management of dysphagia and gastroparesis in Parkinson\u2019s disease in real-world clinical practice\u2013Balancing pharmacological and non-pharmacological approaches","volume":"14","author":"Bhidayasiri","year":"2022","journal-title":"Front. Aging Neurosci."},{"issue":"5","key":"10.1016\/j.ejpb.2026.115179_b0175","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1111\/ene.15734","article-title":"Gastrointestinal barriers to levodopa transport and absorption in Parkinson's disease","volume":"30","author":"Leta","year":"2023","journal-title":"Eur. J. Neurol."},{"issue":"1","key":"10.1016\/j.ejpb.2026.115179_b0180","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/s41467-019-08294-y","article-title":"Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson\u2019s disease","volume":"10","author":"van Kessel","year":"2019","journal-title":"Nat. Commun."},{"issue":"6445","key":"10.1016\/j.ejpb.2026.115179_b0185","doi-asserted-by":"crossref","DOI":"10.1126\/science.aau6323","article-title":"Discovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism","volume":"364","author":"Maini Rekdal","year":"2019","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.ejpb.2026.115179_b0190","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s40263-024-01073-4","article-title":"The gut microbiota in Parkinson disease: interactions with drugs and potential for therapeutic applications","volume":"38","author":"Menozzi","year":"2024","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ejpb.2026.115179_b0195","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1046910","article-title":"A review of studies on gut microbiota and levodopa metabolism","volume":"14","author":"Zhong","year":"2023","journal-title":"Front. Neurol."},{"issue":"1\u20132","key":"10.1016\/j.ejpb.2026.115179_b0200","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jns.2012.05.010","article-title":"Plasma levodopa peak delay and impaired gastric emptying in Parkinson's disease","volume":"319","author":"Doi","year":"2012","journal-title":"J. Neurol. Sci."},{"issue":"5","key":"10.1016\/j.ejpb.2026.115179_b0205","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1080\/17425255.2020.1750596","article-title":"Pharmacokinetics and pharmacodynamics of levodopa\/carbidopa cotherapies for Parkinson\u2019s disease","volume":"16","author":"M\u00fcller","year":"2020","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"1","key":"10.1016\/j.ejpb.2026.115179_b0210","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/s41598-021-04356-8","article-title":"Impact of age at onset on symptom profiles, treatment characteristics and health-related quality of life in Parkinson\u2019s disease","volume":"12","author":"Raket","year":"2022","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.ejpb.2026.115179_b0215","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.parkreldis.2014.02.019","article-title":"Small intestinal bacterial overgrowth in Parkinson's disease","volume":"20","author":"Tan","year":"2014","journal-title":"Parkinsonism Relat. Disord."},{"issue":"21","key":"10.1016\/j.ejpb.2026.115179_b0220","doi-asserted-by":"crossref","first-page":"11663","DOI":"10.3390\/ijms222111663","article-title":"Small intestinal bacterial overgrowth as potential therapeutic target in Parkinson\u2019s disease","volume":"22","author":"D\u0103n\u0103u","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejpb.2026.115179_b0225","doi-asserted-by":"crossref","unstructured":"Maini Rekdal, Vayu, Elizabeth N. Bess, Jordan E. Bisanz, Peter J. Turnbaugh, and Emily P. Balskus. \u201cDiscovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism.\u201dScience364, no. 6445 (2019): eaau6323.","DOI":"10.1126\/science.aau6323"},{"issue":"7","key":"10.1016\/j.ejpb.2026.115179_b0230","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.2174\/1570159X21666221019115716","article-title":"Relationship between gut bacteria and levodopa metabolism","volume":"21","author":"Xu","year":"2023","journal-title":"Curr. Neuropharmacol."},{"issue":"2","key":"10.1016\/j.ejpb.2026.115179_b0235","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/WNF.0b013e31824523de","article-title":"Pharmacokinetics and pharmacodynamics of gastroretentive delivery of levodopa\/carbidopa in patients with Parkinson disease","volume":"35","author":"Chen","year":"2012","journal-title":"Clin. Neuropharmacol."},{"issue":"3","key":"10.1016\/j.ejpb.2026.115179_b0240","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.parkreldis.2010.11.002","article-title":"Influence of ageing on the pharmacokinetics of levodopa in elderly patients with Parkinson\u2019s disease","volume":"17","author":"Nagayama","year":"2011","journal-title":"Parkinsonism Relat. Disord."},{"issue":"1","key":"10.1016\/j.ejpb.2026.115179_b0245","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41531-022-00321-y","article-title":"Mechanisms of peripheral levodopa resistance in Parkinson\u2019s disease","volume":"8","author":"Beckers","year":"2022","journal-title":"npj Parkinson's Dis."},{"issue":"1","key":"10.1016\/j.ejpb.2026.115179_b0250","article-title":"Intrajejunal levodopa infusion in advanced Parkinson's disease: long-term effects on motor and non-motor symptoms and impact on patient's and caregiver's quality of life","volume":"16","author":"Fasano","year":"2012","journal-title":"European Review for Medical & Pharmacological Sciences"},{"issue":"3","key":"10.1016\/j.ejpb.2026.115179_b0255","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.parkreldis.2014.12.012","article-title":"Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes","volume":"21","author":"Antonini","year":"2015","journal-title":"Parkinsonism Relat. Disord."},{"issue":"46","key":"10.1016\/j.ejpb.2026.115179_b0260","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000023249","article-title":"Intrajejunal vs oral levodopa-carbidopa therapy in Parkinson disease: A retrospective cohort study","volume":"99","author":"Popa","year":"2020","journal-title":"Medicine"},{"issue":"5","key":"10.1016\/j.ejpb.2026.115179_b0265","doi-asserted-by":"crossref","first-page":"925","DOI":"10.3233\/JPD-230372","article-title":"Effectiveness of continuous dopaminergic therapies in Parkinson\u2019s disease: A review of L-DOPA pharmacokinetics\/pharmacodynamics","volume":"14","author":"Demailly","year":"2024","journal-title":"Journal of Parkinson\u2019s Disease"},{"issue":"2","key":"10.1016\/j.ejpb.2026.115179_b0270","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1474-4422(13)70293-X","article-title":"Double-blind, double-dummy, randomized study of continuous intrajejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson\u2019s disease","volume":"13","author":"Olanow","year":"2014","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.ejpb.2026.115179_b0275","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3233\/JPD-161042","article-title":"Levodopa-carbidopa intestinal gel pharmacokinetics: lower variability than oral levodopa-carbidopa","volume":"7","author":"Othman","year":"2017","journal-title":"Journal of Parkinson\u2019s Disease"},{"issue":"9","key":"10.1016\/j.ejpb.2026.115179_b0280","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1002\/mds.25522","article-title":"The role of small intestinal bacterial overgrowth in Parkinson's disease","volume":"28","author":"Fasano","year":"2013","journal-title":"Mov. Disord."},{"issue":"2","key":"10.1016\/j.ejpb.2026.115179_b0285","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/mdc3.13593","article-title":"Intermittent apomorphine use for off period rescue in Parkinson's disease: a pragmatic review of over three decades of clinical experience","volume":"10","author":"Castillo-Torres","year":"2023","journal-title":"Movement Disorders Clinical Practice"},{"issue":"9","key":"10.1016\/j.ejpb.2026.115179_b0290","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s40263-019-00661-z","article-title":"Apomorphine for Parkinson\u2019s disease: efficacy and safety of current and new formulations","volume":"33","author":"Carbone","year":"2019","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ejpb.2026.115179_b0295","unstructured":"U.S. FDA Approves VYALEV\u2122 (foscarbidopa and foslevodopa) for Adults Living with Advanced Parkinson's Disease - Oct 17, 2024 label."},{"key":"10.1016\/j.ejpb.2026.115179_b0300","unstructured":"U.S. Food and Drug Administration (FDA). Clinical Pharmacology and Biopharmaceutics Review(s): VYALEV\u2122 (foscarbidopa\/foslevodopa), Application Number 216962Orig1s000. Center for Drug Evaluation and Research (CDER), Office of Clinical Pharmacology; 2024."},{"key":"10.1016\/j.ejpb.2026.115179_b0305","unstructured":"U.S. Food and Drug Administration (FDA). Clinical Review(s): VYALEV\u2122 (foscarbidopa\/foslevodopa). Application No. 216962Orig1s000. Center for Drug Evaluation and Research (CDER); 2024."},{"key":"10.1016\/j.ejpb.2026.115179_b0310","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.2147\/NDT.S147633","article-title":"Profile of inhaled levodopa and its potential in the treatment of Parkinson\u2019s disease: evidence to date","author":"Patel","year":"2018","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.ejpb.2026.115179_b0315","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.parkreldis.2019.12.012","article-title":"Inhaled levodopa in Parkinson's disease patients with OFF periods: a randomized 12-month pulmonary safety study","volume":"71","author":"Grosset","year":"2020","journal-title":"Parkinsonism Relat. Disord."},{"issue":"1","key":"10.1016\/j.ejpb.2026.115179_b0320","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3390\/app15010331","article-title":"Nanocarriers-Assisted Nose-to-Brain Delivery of Levodopa: Current Progress and Prospects","volume":"15","author":"Dangova","year":"2024","journal-title":"Appl. Sci."},{"key":"10.1016\/j.ejpb.2026.115179_b0325","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jconrel.2023.06.026","article-title":"Levodopa-loaded nanoparticles for the treatment of Parkinson's disease","volume":"360","author":"van Vliet","year":"2023","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.ejpb.2026.115179_b0330","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/s41531-025-01081-1","article-title":"Revamping Parkinson\u2019s disease therapy using PLGA-based drug delivery systems","volume":"11","author":"Lababidi","year":"2025","journal-title":"npj Parkinson's Dis."},{"key":"10.1016\/j.ejpb.2026.115179_b0335","doi-asserted-by":"crossref","unstructured":"Kakono, C., Witika, B.A., Makoni, P.A. and Walker, R.B., 2025. Cationic Nanocrystalline Suspensions: A Potential Approach for Nose to Brain Delivery of L-Dopa in Parkinson's Therapy.Pharmaceutical Development and Technology, (just-accepted), pp.1-22.","DOI":"10.1080\/10837450.2025.2516237"},{"issue":"2","key":"10.1016\/j.ejpb.2026.115179_b0340","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.mayocp.2020.08.001","article-title":"February. Dysphagia in older adults","volume":"96","author":"Thiyagalingam","year":"2021","journal-title":"In Mayo clinic proceedings (Vol."},{"issue":"4","key":"10.1016\/j.ejpb.2026.115179_b0345","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.3390\/pharmaceutics15041042","article-title":"Impact of tablet size and shape on the swallowability in older adults","volume":"15","author":"Hummler","year":"2023","journal-title":"Pharmaceutics"},{"issue":"10","key":"10.1016\/j.ejpb.2026.115179_b0350","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1080\/1061186X.2024.2386626","article-title":"Geriatric drug delivery\u2015barriers, current technologies and the road ahead","volume":"32","author":"Kean","year":"2024","journal-title":"J. Drug Target."},{"issue":"1","key":"10.1016\/j.ejpb.2026.115179_b0355","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3390\/pharmaceutics13010032","article-title":"Better medicines for older patients: considerations between patient characteristics and solid oral dosage form designs to improve swallowing experience","volume":"13","author":"Drumond","year":"2020","journal-title":"Pharmaceutics"},{"issue":"12","key":"10.1016\/j.ejpb.2026.115179_b0360","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-018151","article-title":"Oral medicine modification for older adults: a qualitative study of nurses","volume":"7","author":"Mc Gillicuddy","year":"2017","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.ejpb.2026.115179_b0365","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.1038\/s41598-024-84627-2","article-title":"Polypharmacy and self-medication among older adults in Indian urban communities-a cross-sectional study","volume":"15","author":"Das","year":"2025","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.ejpb.2026.115179_b0370","doi-asserted-by":"crossref","DOI":"10.1177\/00368504211070183","article-title":"Prevalence of polypharmacy and risk of potential drug-drug interactions among hospitalized patients with emphasis on the pharmacokinetics","volume":"105","author":"Georgiev","year":"2022","journal-title":"Sci. Prog."},{"issue":"10","key":"10.1016\/j.ejpb.2026.115179_b0375","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1111\/bcp.14094","article-title":"Prescribing medicines to older people\u2014How to consider the impact of ageing on human organ and body functions","volume":"86","author":"Drenth-van Maanen","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejpb.2026.115179_b0380","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2018.09.003","article-title":"Challenges and innovations of drug delivery in older age","volume":"135","author":"Khan","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.ejpb.2026.115179_b0385","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1186\/s12951-022-01539-x","article-title":"Mucus interaction to improve gastrointestinal retention and pharmacokinetics of orally administered nano-drug delivery systems","volume":"20","author":"Subramanian","year":"2022","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.ejpb.2026.115179_b0390","article-title":"Khushwant S","volume":"259","author":"Muzaffaruddin Ahmed Madny","year":"2026","journal-title":"Yadav, Biomimetic oral drug delivery: Translating nature\u2019s design into therapeutic innovation, Colloids and Surfaces B: Biointerfaces"},{"issue":"1","key":"10.1016\/j.ejpb.2026.115179_b0395","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s12951-023-01949-5","article-title":"Oral membrane-biomimetic nanoparticles for enhanced endocytosis and regulation of tumor-associated macrophage","volume":"21","author":"Gu","year":"2023","journal-title":"J. Nanobiotechnol."},{"issue":"1","key":"10.1016\/j.ejpb.2026.115179_b0400","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1186\/s12951-024-02930-6","article-title":"Intestinal nanoparticle delivery and cellular response: a review of the bidirectional nanoparticle-cell interplay in mucosa based on physiochemical properties","volume":"22","author":"Wang","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.ejpb.2026.115179_b0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.115130","article-title":"Nanocarriers transport across the gastrointestinal barriers: the contribution to oral bioavailability via blood circulation and lymphatic pathway","volume":"203","author":"Wang","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.ejpb.2026.115179_b0410","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1038\/s41598-024-84322-2","article-title":"Oral colon-targeted responsive chitosan\/pectin-based nanoparticles propels the application of tofacitinib in colitis therapy","volume":"15","author":"Wu","year":"2025","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.ejpb.2026.115179_b0415","article-title":"Innovations in Parkinson\u2019s Disease: Strategies and Novel Technologies","volume":"17","author":"Sha","year":"2025","journal-title":"Cureus"},{"issue":"5","key":"10.1016\/j.ejpb.2026.115179_b0420","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.3390\/pharmaceutics15051503","article-title":"The management of Parkinson\u2019s disease: an overview of the current advancements in drug delivery systems","volume":"15","author":"Nakmode","year":"2023","journal-title":"Pharmaceutics"},{"issue":"10","key":"10.1016\/j.ejpb.2026.115179_b0425","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.3390\/pharmaceutics13101591","article-title":"Gastroretentive technologies in tandem with controlled-release strategies: A potent answer to oral drug bioavailability and patient compliance implications","volume":"13","author":"Vrettos","year":"2021","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.ejpb.2026.115179_b0430","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s13346-022-01188-5","article-title":"Development and characterization of gastro-floating sustained-release capsule with improved bioavailability of levodopa","volume":"13","author":"Yuan","year":"2023","journal-title":"Drug Deliv. Transl. Res."},{"issue":"9","key":"10.1016\/j.ejpb.2026.115179_b0435","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1002\/mds.26219","article-title":"Gastroretentive carbidopa\/levodopa, DM\u20101992, for the treatment of advanced Parkinson's disease","volume":"30","author":"Verhagen Metman","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ejpb.2026.115179_b0440","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2025.114633","article-title":"A novel levodopa-carbidopa three-layer gastroretentive tablet for improving levodopa pharmacokinetics","volume":"207","author":"Zhao","year":"2025","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"7","key":"10.1016\/j.ejpb.2026.115179_b0445","doi-asserted-by":"crossref","first-page":"433","DOI":"10.4155\/tde-2018-0067","article-title":"The Accordion Pill\u00ae: unique oral delivery to enhance pharmacokinetics and therapeutic benefit of challenging drugs","volume":"10","author":"Navon","year":"2019","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.ejpb.2026.115179_b0450","first-page":"1","article-title":"Development of an in-situ forming implant system for levodopa and carbidopa for the treatment of parkinson\u2019s disease","author":"Nakmode","year":"2025","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.ejpb.2026.115179_b0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2025.107201","article-title":"Rational design and DoE based prediction model for levodopa gastroretentive systems based on hot-melt tube extrusion","volume":"111","author":"Bebernik","year":"2025","journal-title":"J. Drug Delivery Sci. Technol."},{"issue":"1","key":"10.1016\/j.ejpb.2026.115179_b0460","doi-asserted-by":"crossref","first-page":"15869","DOI":"10.1038\/s41598-023-42878-5","article-title":"Model-based optimization of controlled release formulation of levodopa for Parkinson\u2019s disease","volume":"13","author":"Arav","year":"2023","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.ejpb.2026.115179_b0465","doi-asserted-by":"crossref","first-page":"16013","DOI":"10.1038\/npjsba.2016.13","article-title":"Model-based dietary optimization for late-stage, levodopa-treated, Parkinson\u2019s disease patients","volume":"2","author":"Guebila","year":"2016","journal-title":"npj Syst. Biol. Appl."},{"issue":"2","key":"10.1016\/j.ejpb.2026.115179_b0470","doi-asserted-by":"crossref","first-page":"138","DOI":"10.14802\/jmd.22220","article-title":"Gastrointestinal dysfunction in Parkinson\u2019s disease: neuro-gastroenterology perspectives on a multifaceted problem","volume":"16","author":"Tan","year":"2023","journal-title":"Journal of movement disorders"},{"issue":"01","key":"10.1016\/j.ejpb.2026.115179_b0475","article-title":"Is Levodopa Pharmacokinetics in Patients with Parkinson\u2019s Disease Depending on Gastric Emptying?","volume":"6","author":"Nord","year":"2017","journal-title":"Advances in Parkinsons Disease"},{"key":"10.1016\/j.ejpb.2026.115179_b0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2023.106496","article-title":"Physiologically based pharmacokinetic (PBPK) modelling of oral drug absorption in older adults\u2013an AGePOP review","volume":"188","author":"Demeester","year":"2023","journal-title":"Eur. J. Pharm. Sci."},{"issue":"11","key":"10.1016\/j.ejpb.2026.115179_b0485","doi-asserted-by":"crossref","first-page":"5282","DOI":"10.3390\/ijms26115282","article-title":"Targeted gut microbiota modulation enhances levodopa bioavailability and motor recovery in MPTP Parkinson\u2019s disease models","volume":"26","author":"Ai","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.ejpb.2026.115179_b0490","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1136\/jech-2023-221829","article-title":"Frailty or frailties: exploring frailty index subdimensions in the English Longitudinal Study of Ageing","volume":"78","author":"Johnson","year":"2024","journal-title":"J. Epidemiol. Community Health"},{"issue":"4","key":"10.1016\/j.ejpb.2026.115179_b0495","doi-asserted-by":"crossref","DOI":"10.1172\/JCI143771","article-title":"Gastrointestinal motility disorders in neurologic disease","volume":"131","author":"Camilleri","year":"2021","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.ejpb.2026.115179_b0500","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41531-021-00260-0","article-title":"Gut bacterial tyrosine decarboxylase associates with clinical variables in a longitudinal cohort study of Parkinsons disease","volume":"7","author":"van Kessel","year":"2021","journal-title":"npj Parkinson's Dis."},{"issue":"6","key":"10.1016\/j.ejpb.2026.115179_b0505","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1097\/00007691-200112000-00005","article-title":"Levodopa therapy monitoring in patients with Parkinson disease: a kinetic\u2013dynamic approach","volume":"23","author":"Contin","year":"2001","journal-title":"Ther. Drug Monit."},{"issue":"12","key":"10.1016\/j.ejpb.2026.115179_b0510","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1111\/j.1365-2648.2011.05700.x","article-title":"Medicine administration errors in patients with dysphagia in secondary care: a multi\u2010centre observational study","volume":"67","author":"Kelly","year":"2011","journal-title":"J. Adv. Nurs."},{"key":"10.1016\/j.ejpb.2026.115179_b0515","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2147\/AMEP.S203680","article-title":"Improving knowledge, attitudes, and practice of nurses in medication administration through enteral feeding tubes by clinical pharmacists: a case\u2013control study","author":"Hossaini Alhashemi","year":"2019","journal-title":"Adv. Med. Educ. Pract."},{"key":"10.1016\/j.ejpb.2026.115179_b0520","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2024.106065","article-title":"\u201cAdvanced\u201d Parkinson's disease: A review","volume":"123","author":"Aslam","year":"2024","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.ejpb.2026.115179_b0525","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.parkreldis.2020.05.001","article-title":"Clinical implications of gastric complications on levodopa treatment in Parkinson's disease","volume":"76","author":"Pfeiffer","year":"2020","journal-title":"Parkinsonism Relat. Disord."},{"issue":"1","key":"10.1016\/j.ejpb.2026.115179_b0530","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1146\/annurev-pharmtox-033020-113257","article-title":"Model-informed precision dosing: background, requirements, validation, implementation, and forward trajectory of individualizing drug therapy","volume":"61","author":"Darwich","year":"2021","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.ejpb.2026.115179_b0535","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2021.105812","article-title":"Impact of gastrointestinal tract variability on oral drug absorption and pharmacokinetics: An UNGAP review","volume":"162","author":"Vinarov","year":"2021","journal-title":"Eur. J. Pharm. Sci."},{"issue":"7762","key":"10.1016\/j.ejpb.2026.115179_b0540","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/s41586-019-1291-3","article-title":"Mapping human microbiome drug metabolism by gut bacteria and their genes","volume":"570","author":"Zimmermann","year":"2019","journal-title":"Nature"},{"issue":"Suppl 2","key":"10.1016\/j.ejpb.2026.115179_b0545","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00415-010-5728-8","article-title":"Pharmacokinetics of levodopa","volume":"257","author":"Contin","year":"2010","journal-title":"J. Neurol."},{"issue":"5","key":"10.1016\/j.ejpb.2026.115179_b0550","doi-asserted-by":"crossref","first-page":"925","DOI":"10.3233\/JPD-230372","article-title":"Effectiveness of continuous dopaminergic therapies in Parkinson\u2019s disease: A review of L-DOPA pharmacokinetics\/pharmacodynamics","volume":"14","author":"Demailly","year":"2024","journal-title":"Journal of Parkinson\u2019s Disease"},{"issue":"1","key":"10.1016\/j.ejpb.2026.115179_b0555","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ijpharm.2016.07.054","article-title":"Age-appropriate and acceptable paediatric dosage forms: Insights into end-user perceptions, preferences and practices from the Children\u2019s Acceptability of Oral Formulations (CALF) Study","volume":"514","author":"Ranmal","year":"2016","journal-title":"Int. J. Pharm."},{"issue":"2","key":"10.1016\/j.ejpb.2026.115179_b0560","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1124\/pr.56.2.4","article-title":"Aging biology and geriatric clinical pharmacology","volume":"56","author":"McLean","year":"2004","journal-title":"Pharmacol. Rev."},{"issue":"1","key":"10.1016\/j.ejpb.2026.115179_b0565","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1046\/j.1365-2125.2003.02007.x","article-title":"Age\u2010related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications","volume":"57","author":"Mangoni","year":"2004","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"12","key":"10.1016\/j.ejpb.2026.115179_b0570","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1080\/03007995.2018.1502165","article-title":"Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson\u2019s disease: a multi-country Delphi-panel approach","volume":"34","author":"Antonini","year":"2018","journal-title":"Curr. Med. Res. Opin."},{"issue":"6","key":"10.1016\/j.ejpb.2026.115179_b0575","doi-asserted-by":"crossref","first-page":"790","DOI":"10.3390\/pharmaceutics16060790","article-title":"Expanding the manufacturing approaches for gastroretentive drug delivery systems with 3D printing technology","volume":"16","author":"Turac","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2026.115179_b0580","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2024.106704","article-title":"Microparticles and multi-unit systems for advanced drug delivery","volume":"194","author":"K\u00e1llai-Szab\u00f3","year":"2024","journal-title":"Eur. J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.ejpb.2026.115179_b0585","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1021\/acsabm.4c01149","article-title":"Biomimetic Approach for Optimal Designing of the Shape and Controlled Release of Therapeutics from Tricompartmental Microcarriers for Managing Parkinson\u2019s Disease","volume":"8","author":"Gupta","year":"2024","journal-title":"ACS Appl. Bio Mater."},{"issue":"5","key":"10.1016\/j.ejpb.2026.115179_b0590","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1080\/10837450.2018.1462471","article-title":"Orally disintegrating tablets, fast-dissolving, buccal and sublingual formulations","volume":"23","author":"\u015eenel","year":"2018","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.ejpb.2026.115179_b0595","doi-asserted-by":"crossref","unstructured":"Bellinger, A.M., Jafari, M., Grant, T.M., Zhang, S., Slater, H.C., Wenger, E.A., Mo, S., Lee, Y.A.L., Mazdiyasni, H., Kogan, L. and Barman, R., 2016. Oral, ultra\u2013long-lasting drug delivery: Application toward malaria elimination goals.Science translational medicine,8(365), pp.365ra157-365ra157.","DOI":"10.1126\/scitranslmed.aag2374"},{"key":"10.1016\/j.ejpb.2026.115179_b0600","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jconrel.2017.07.043","article-title":"Tablets of multi-unit pellet system for controlled drug delivery","volume":"262","author":"Chen","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2026.115179_b0605","unstructured":"E7 Studies in Support of Special Populations: Geriatrics | FDA; ICHE7."},{"issue":"3","key":"10.1016\/j.ejpb.2026.115179_b0610","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/cpt.2793","article-title":"Assessing medicines for use in the geriatric population","volume":"113","author":"Cerreta","year":"2023","journal-title":"Clin. Pharmacol. Ther."},{"issue":"12","key":"10.1016\/j.ejpb.2026.115179_b0615","doi-asserted-by":"crossref","first-page":"e724","DOI":"10.1016\/S2666-7568(23)00208-8","article-title":"Inclusion of functional measures and frailty in the development and evaluation of medicines for older adults","volume":"4","author":"Denkinger","year":"2023","journal-title":"The Lancet Healthy Longevity"},{"key":"10.1016\/j.ejpb.2026.115179_b0620","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2024.115364","article-title":"Model-informed drug development in pediatric, pregnancy and geriatric drug development: States of the art and future","volume":"211","author":"Wu","year":"2024","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"6","key":"10.1016\/j.ejpb.2026.115179_b0625","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1208\/s12248-025-01155-1","article-title":"Physiologically based pharmacokinetic modeling and simulation in regulatory review: US FDA CBER experience and perspectives","volume":"27","author":"Tegenge","year":"2025","journal-title":"AAPS J."},{"key":"10.1016\/j.ejpb.2026.115179_b0630","unstructured":"ICH Official web site : ICH, ICH_M15_Step4_Final_Guideline_2026_0129.pdf."},{"issue":"3","key":"10.1016\/j.ejpb.2026.115179_b0635","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s40262-025-01494-4","article-title":"Correction: Influence of Ageing on the Pharmacodynamics and Pharmacokinetics of Chronically Administered Medicines in Geriatric Patients: A Review","volume":"64","author":"Ngcobo","year":"2025","journal-title":"Clin. Pharmacokinet."},{"issue":"1","key":"10.1016\/j.ejpb.2026.115179_b0640","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3233\/JPD-202298","article-title":"Effects of Helicobacter pylori on levodopa pharmacokinetics","volume":"11","author":"Nyholm","year":"2021","journal-title":"Journal of Parkinson\u2019s Disease"},{"key":"10.1016\/j.ejpb.2026.115179_b0645","doi-asserted-by":"crossref","unstructured":"Hasriza Hashim, H.H., Shahrul Azmin, S.A., Hamizah Razlan, H.R., Nafisah Wan Yahya, N.W.Y., Tan HuiJan, T.H., Manaf, M.R.A. and Norlinah Mohamed Ibrahim, N.M.I., 2014. Eradication of Helicobacter pylori infection improves levodopa action, clinical symptoms and quality of life in patients with Parkinson's disease.","DOI":"10.1371\/journal.pone.0112330"},{"issue":"5","key":"10.1016\/j.ejpb.2026.115179_b0650","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/ene.13895","article-title":"Early\u2010morning OFF and levodopa dose failures in patients with Parkinson's disease attending a routine clinical appointment using Time\u2010to\u2010ON Questionnaire","volume":"26","author":"Stocchi","year":"2019","journal-title":"Eur. J. Neurol."},{"issue":"4","key":"10.1016\/j.ejpb.2026.115179_b0655","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/00002826-200307000-00009","article-title":"Waiting for ON: a major problem in patients with Parkinson disease and ON\/OFF motor fluctuations","volume":"26","author":"Merims","year":"2003","journal-title":"Clin. Neuropharmacol."},{"issue":"12","key":"10.1016\/j.ejpb.2026.115179_b0660","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/S1474-4422(22)00400-8","article-title":"Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial","volume":"21","author":"Soileau","year":"2022","journal-title":"The Lancet Neurology"}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641126002006?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641126002006?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:39:56Z","timestamp":1790109596000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641126002006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":132,"alternative-id":["S0939641126002006"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2026.115179","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ageing-driven gastrointestinal variability in Parkinson\u2019s disease: implications for oral levodopa pharmacokinetics and formulation design","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2026.115179","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115179"}}